Eton Pharmaceuticals, INC. (ETON) — SEC Filings

Overview

Eton Pharmaceuticals, INC. (ETON) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 8-K filed on Apr 16, 2026: Eton Pharmaceuticals, Inc. announced on April 16, 2026, the appointment of a new Chief Financial Officer (CFO). The press release, filed as Exhibit 99.1, details this executive change.

Sentiment Summary

Across 47 filings, the sentiment breakdown is: 1 bullish, 43 neutral, 3 mixed. The dominant filing sentiment for Eton Pharmaceuticals, INC. is neutral.

Filing Type Overview

Eton Pharmaceuticals, INC. (ETON) has filed 32 8-K, 4 8-K/A, 4 10-Q, 2 DEF 14A, 1 10-K, 1 SC 13G, 2 SC 13G/A, 1 SC 13D/A with the SEC between Feb 2024 to Apr 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (47)

• Eton Pharmaceuticals Appoints New CFO — 8-K · Apr 16, 2026 Risk: low
  Eton Pharmaceuticals, Inc. announced on April 16, 2026, the appointment of a new Chief Financial Officer (CFO). The press release, filed as Exhibit 99.1, detail
• 8-K Filing — 8-K · Dec 4, 2025
• Eton Pharmaceuticals Files 8-K/A for Asset Acquisition — 8-K/A · Nov 18, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K/A on November 18, 2025, to amend its previous filing regarding the completion of an acquisition or disposition of assets
• Eton Pharma's Revenue Soars 114%, But Net Loss Widens to $6.08M — 10-Q · Nov 6, 2025 Risk: medium
  Eton Pharmaceuticals, Inc. reported a significant increase in total net revenues for the nine months ended September 30, 2025, reaching $58,669 thousand, a subs
• Eton Pharma Sees Revenue Surge in Q2 2025 on Product Sales — 10-Q · Aug 7, 2025 Risk: high
  Eton Pharmaceuticals, Inc. reported a significant increase in total revenue for the three months ended June 30, 2025, reaching $10,000 compared to $0 in the pri
• Eton Pharmaceuticals Files 8-K — 8-K · Jul 8, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on July 8, 2025, to report other events and financial statements. The filing does not contain specific details about the
• Eton Pharmaceuticals Files 8-K — 8-K · Jun 27, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on June 27, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specific
• Eton Pharmaceuticals Changes Auditors — 8-K · Jun 20, 2025 Risk: low
  Eton Pharmaceuticals, Inc. announced on June 13, 2025, a change in its certifying accountant. The company has dismissed its previous independent registered publ
• Eton Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jun 10, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on June 10, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's cor
• Eton Pharmaceuticals Files 8-K — 8-K · May 28, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on May 28, 2025, reporting other events and financial statements. The filing does not contain specific details about the
• Eton Pharmaceuticals Files 8-K on Financials — 8-K · May 13, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, as well as filing financial statements
• Eton Pharmaceuticals Files 8-K/A for Increlex Update — 8-K/A · May 2, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K/A on May 2, 2025, to amend its previous filing from December 19, 2024. The amendment concerns an accounting and reportin
• Eton Pharmaceuticals Files 8-K — 8-K · Apr 28, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on April 28, 2025, reporting other events and financial statements. The filing does not contain specific details about n
• Eton Pharmaceuticals Files Annual Proxy Statement — DEF 14A · Apr 25, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed a DEF 14A on April 25, 2025, for the fiscal year ending December 31, 2024. The filing provides details on executive compensatio
• Eton Pharmaceuticals Files 8-K for Financials and Exhibits — 8-K · Apr 1, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on April 1, 2025, reporting on events that occurred on March 31, 2025. The filing primarily concerns financial statement
• Eton Pharmaceuticals Files 2024 10-K — 10-K · Mar 18, 2025 Risk: medium
  Eton Pharmaceuticals, Inc. filed its 2024 10-K on March 18, 2025, reporting its fiscal year ended December 31, 2024. The company's financial statements indicate
• Eton Pharmaceuticals Files 8-K — 8-K · Mar 14, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on March 14, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain specifi
• Eton Pharma Amends 8-K for Increlex Deal — 8-K/A · Mar 7, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K/A on March 7, 2025, to amend its previous filing regarding the acquisition of assets related to Increlex. The amendment
• Eton Pharmaceuticals Files 8-K — 8-K · Mar 3, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on March 3, 2025, reporting other events and financial statements. The filing details the company's principal executive
• Eton Pharmaceuticals Files 8-K — 8-K · Feb 7, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on February 7, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The filing does not contain speci
• Eton Pharmaceuticals Files 8-K — 8-K · Feb 6, 2025 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on February 6, 2025, reporting other events and financial statements. The filing details the company's corporate structu
• Eton Pharmaceuticals Completes 03 Life Sciences Acquisition — 8-K · Jan 3, 2025 Risk: medium
  Eton Pharmaceuticals, Inc. announced the completion of its acquisition of 100% of the outstanding equity interests in 03 Life Sciences on December 31, 2024. Thi
• Eton Pharma Completes Asset Acquisition — 8-K · Dec 20, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced the completion of its acquisition of certain assets from 03 Life Sciences on December 19, 2024. The filing does not disclos
• Eton Pharmaceuticals to be Acquired by Luye Pharma Group — 8-K · Dec 17, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced on December 17, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Luye Pharma Group L
• Eton Pharmaceuticals Enters Material Definitive Agreement — 8-K · Dec 12, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced on December 10, 2024, that it has entered into a material definitive agreement. The filing does not disclose specific detai
• SC 13G Filing — SC 13G · Dec 9, 2024
• Eton Pharmaceuticals Files 8-K — 8-K · Dec 3, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on December 3, 2024, to report other events and financial statements. The filing does not contain specific details about
• Eton Pharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 25, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced on November 22, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details o
• Eton Pharmaceuticals Q3 2024 10-Q Filed — 10-Q · Nov 12, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. filed its Q3 2024 10-Q report on November 12, 2024, for the period ending September 30, 2024. The company's financial statements show
• Eton Pharmaceuticals Files 8-K — 8-K · Nov 7, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on November 7, 2024, reporting on events that occurred on November 5, 2024. The filing primarily concerns other events a
• Eton Pharmaceuticals Enters Material Definitive Agreement — 8-K · Oct 3, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced on October 2, 2024, that it entered into a material definitive agreement. The filing does not disclose specific details of
• SC 13G/A Filing — SC 13G/A · Sep 12, 2024
• Eton Pharmaceuticals Files 8-K on Financials — 8-K · Aug 8, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on August 8, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
• Eton Pharmaceuticals Files 8-K/A on Say on Pay Vote Frequency — 8-K/A · Aug 2, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K/A amendment on August 2, 2024, related to the matters submitted to a vote of security holders on June 11, 2024. This fil
• Eton Pharmaceuticals Files 8-K — 8-K · Jul 15, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on July 15, 2024, to report other events and financial statements. The filing details the company's principal executive
• 3D Systems to Acquire Eton Pharmaceuticals for $1.2B — 8-K · Jun 21, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. announced on June 14, 2024, that it has entered into a definitive agreement to be acquired by 3D Systems Corporation for approximatel
• Eton Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jun 11, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on June 11, 2024, to report on matters submitted to a vote of its security holders. The filing details the company's cor
• Eton Pharmaceuticals, Inc. Files 10-Q for Q1 2024 — 10-Q · May 9, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. (ETON) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Eton Pharmaceuticals, Inc. filed a 10-Q report for the period end
• Harrow, Inc. Amends Eton Pharmaceuticals Stake Filing — SC 13D/A · Apr 30, 2024 Risk: medium
  Harrow, Inc. filed an amendment (SC 13D/A) on April 30, 2024, regarding their ownership in Eton Pharmaceuticals, Inc. The filing indicates a change in the benef
• Eton Pharmaceuticals Files 8-K — 8-K · Apr 30, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on April 30, 2024, reporting other events and financial statements. The filing does not contain specific financial figur
• Eton Pharmaceuticals, Inc. Files Definitive Proxy Statement (DEF 14A) — DEF 14A · Apr 26, 2024 Risk: low
  Eton Pharmaceuticals, Inc. (ETON) filed a Proxy Statement (DEF 14A) with the SEC on April 26, 2024. Eton Pharmaceuticals, Inc. filed a Definitive Proxy Statemen
• Eton Pharmaceuticals Reports Unregistered Equity Sales — 8-K · Apr 18, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. filed an 8-K on April 18, 2024, reporting unregistered sales of equity securities. The filing details transactions that occurred on A
• Eton Pharmaceuticals Files 8-K — 8-K · Mar 22, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on March 22, 2024, to report other events and financial statements. The filing does not contain specific details about n
• Eton Pharmaceuticals Files 8-K on Financials — 8-K · Mar 14, 2024 Risk: low
  Eton Pharmaceuticals, Inc. filed an 8-K on March 14, 2024, reporting on its results of operations and financial condition. The filing includes financial stateme
• Eton Pharmaceuticals Files 8-K for 'Other Event' and Financial Exhibits — 8-K · Feb 21, 2024 Risk: medium
  Eton Pharmaceuticals, Inc. filed an 8-K on February 21, 2024, reporting an "Other Event" and "Financial Statements and Exhibits." The filing indicates a current
• Opaleye Management Amends Eton Pharma Stake (Amendment No. 6) — SC 13G/A · Feb 9, 2024 Risk: low
  Opaleye Management Inc., an investment firm based in Boston, MA, filed an amended SC 13G/A on February 9, 2024, indicating a change in their beneficial ownershi
• Eton Pharma Files Routine 8-K; No Major News Reported — 8-K · Feb 2, 2024
  Eton Pharmaceuticals, Inc. filed an 8-K on February 2, 2024, to report 'Other Events' and 'Financial Statements and Exhibits.' This filing indicates standard, r

Related Companies

ETN · DDD · ETRN

Frequently Asked Questions